Providing health care in conflict settings: a call for papers

Bulletin of the World Health Organization
Volume 97, Number 5, May 2019, 309-376
https://www.who.int/bulletin/volumes/97/5/en/

 

EDITORIALS
Providing health care in conflict settings: a call for papers
— Flavio Salio & Altaf Musani
http://dx.doi.org/10.2471/BLT.19.232769
People living in conflict-affected areas incur physical and psychological trauma. They are also vulnerable to disease outbreaks and disruptions in the supply of food and water, medicines and health services. High-quality, accessible medical care is very difficult to provide in such settings. The Geneva Conventions hold warring parties accountable for the provision of care to civilians and combatants. However, these parties may not be willing or able to provide medical assistance to conflict-affected populations. Recent major conflicts, such as in Mosul, Iraq and Al Raqqa, Syrian Arab Republic, have moved health and humanitarian assistance closer to the frontline and challenged the risk-averse approach of traditional responders.
Accountability to affected populations, as defined by the Inter-Agency Standing Committee,1 requires humanitarian responders to provide quality assistance in a timely manner while upholding best practices. Medical ethics and international humanitarian law also bind health practitioners to an operational and accountability framework. When warring parties fail to provide care and assistance to civilians, there is still an imperative to save lives and reduce suffering.
The recent experiences of humanitarian responders show that operational guidance on the provision of trauma care in conflict settings is needed. These experiences also constitute valuable lessons, from which best practices can be identified and future responses improved. An assessment of response in Mosul found that the “WHO-coordinated efforts helped address critical needs in the provision of trauma care for wounded civilians and saved lives.”2,3 However, the referral pathway used in this response created a complex system of care that could not be used by all humanitarian actors because of proximity to the frontlines and to military personnel.2 WHO recognized the operational, technical and ethical dilemmas of the response, trying to balance battlefield care and medical ethics with the humanitarian principles of neutrality, impartiality, humanity and independence.4 WHO emphasized its role as a provider of last resort, and called for partners to work closer to the frontlines. The debate generated by the referral pathway shows that research is needed on issues of quality of, and access to, timely trauma care, on prevention of attacks on health-care workers, transport, patients and facilities, as well as on outbreak prevention and response.
Most research on trauma care in conflict settings has been done in the context of symmetric warfare, when humanitarian agencies have equal access to all warring parties and the wounded, and where the military is the main provider of care. This research led to changes in care provision at the frontline, where the risk of functional impairment is usually highest. Rapid evacuation from the location of injury to the care facility is needed to save lives and reduce disabilities. Despite hard-won experience gathered by many military, United Nations, nongovernmental, civilian and humanitarian actors, there is very limited research on health-care provision and civilian protection in asymmetric warfare, where humanitarian agencies have no access to one or more warring party.
To build the evidence base for future responses, the Bulletin of the World Health Organization encourages submissions to its research, policy-and-practice and lessons-from-the-field sections to shape policy and improve health outcomes in conflict settings.

Ensuring access to life-saving medicines as countries shift from Global Fund support

Bulletin of the World Health Organization
Volume 97, Number 5, May 2019, 309-376
https://www.who.int/bulletin/volumes/97/5/en/

Ensuring access to life-saving medicines as countries shift from Global Fund support
— Mercedes Tatay & Els Torreele
http://dx.doi.org/10.2471/BLT.19.234468
he Global Fund to Fight AIDS, Tuberculosis and Malaria has helped the scale-up of life-saving treatments through affordable, quality-assured medicines and diagnostics. However, faced with stagnating donor health funding,1 in recent years the Global Fund has revised its allocation model2 and its sustainability, transitions and co-financing policies.3

These policies are driving changes that can have negative implications for people with human immunodeficiency virus (HIV), tuberculosis or malaria. Higher prices of medicines, more use of medicines of unknown quality and more unstable supplies increase the risk of more deaths from these three preventable, treatable diseases, and exacerbate the growing global health challenge of serious drug-resistant infections.4 The changes also risk undermining opportunities to scale up life-saving innovations. Such innovations include the first new tuberculosis drugs in 40 years,5 the most effective first-line antiretroviral regimen,6 and a combination diagnostic platform for HIV, tuberculosis and other pathologies.7

The Global Fund’s revised allocation model continues to prioritize countries with the highest disease burdens and lowest incomes, but presses deprioritized countries to more rapidly mobilize alternative (especially domestic) funds to avoid reversing progress in access to life-saving medicines. Furthermore, the revised sustainability, transitions and co-financing policy requires all countries, even those with the lowest incomes, to increase their co-financing of disease programmes, including through purchasing medicines and diagnostics. Consequently, many countries shift sooner than anticipated from Global Fund-supported procurement mechanisms to national procurement processes. However, the shift to increased national procurement risks sacrificing the lower prices, quality assurance and sustainable supplies that come with Global Fund procurement.

The benefits of Global Fund-supported procurement have been achieved largely through the pooled procurement mechanism for HIV and malaria, and the Global Drug Facility for tuberculosis. These pooled, high-volume orders aggregate demand and have therefore attracted multiple suppliers offering competitive prices. In contrast, single countries need smaller volumes, which fragments demand and draws fewer suppliers or fails to interest manufacturers altogether. National procurement therefore often leaves countries with reduced negotiating power, less competition and higher prices.

Negative effects of these shifts are already apparent in some countries. From October 2016 to October 2018, 21 low- and middle-income countries paid higher prices for tuberculosis drugs and diagnostics than they would have through the Global Drug Facility procurement, while 15 countries shifting to national procurement experienced tuberculosis drug stock-outs.8

Another negative consequence of the Global Fund’s policy shifts relates to medicine quality. Medicines procured with Global Fund support are approved by the World Health Organization’s (WHO) pre-qualification programme or a stringent regulatory authority, such as the United States of America Food and Drug Administration. Most national procurement processes do not require WHO’s pre-qualification or regulatory authority approval, and some domestic regulatory authorities may not have the capacity to fully assess the quality and safety of medicines. Therefore, these processes introduce the risk of purchasing products of unknown quality. Between 2016 and 2018, 29 low- and middle-income countries purchased tuberculosis medicines of unknown quality and five purchased diagnostics of unknown quality.8

Finally, Global Fund-supported procurement circumvents the problem of pharmaceutical companies failing to register products in countries considered unattractive markets. Without the import waivers given to products procured from the Global Fund, the lack of local registration risks leading to failed tenders and lack of availability, as has already happened in some countries.

We suggest that the Global Fund, its partners and governments should undertake several steps to address this issue. The Global Fund should conduct risk and readiness assessments for countries shifting to national procurement, exempting them from such co-financing commitments if problems are identified. Donor countries should meet funding targets of the Global Fund,9 support affected countries in establishing strong procurement practices, and fund mechanisms that help countries optimize procurement. Countries should also revise their procurement requirements to allow the use of global and pooled mechanisms for certain life-saving products. Lastly, national tenders should adopt quality assurance requirements.

The Global Fund and WHO’s governing bodies could address these issues at their upcoming meetings in May. Their joint action is needed to avoid setbacks in scaling up affordable, quality medical tools that can prevent the deaths of people with HIV, tuberculosis or malaria.

Evaluation of worldwide clinical trials by gender: An FDA perspective

Contemporary Clinical Trials
Volume 80 Pages 1-62 (May 2019)
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/80/suppl/C

 

Research article Abstract only
Evaluation of worldwide clinical trials by gender: An FDA perspective
Emily Ayuso, Ruth J. Geller, Junyang Wang, John Whyte, Marjorie Jenkins
Pages 16-21
Abstract
Introduction
The US Food and Drug Administration (FDA) has undertaken efforts to promote representation of women in clinical trials. The objectives of this research are to assess women’s participation in clinical trials from a global perspective and to analyze the demographic characteristics of clinical trial participants.
Methods
FDA’s Center for Drug Evaluation and Research-Professional Affairs and Stakeholder Engagement (CDER/PASE) and Office of Women’s Health (OWH) collaborated to evaluate demographic data (race, ethnicity, gender, and age) of pivotal trials of New Molecular Entities (NMEs) approved in 2015–2016 by geographic location. One hundred fifty-four pivotal clinical trials supporting 66 NMEs were identified, and the research team analyzed demographic characteristics of 131,749 participants from 70 countries.
Results
U.S. sites contributed 31% of the 131,749 study participants. On the country level, the United States contributed the largest number of participants and other individual countries contributed 5% or less of the total trial population. Overall, 43% (n = 56,272) of the 131,747 clinical trial participants were women. Of the 40,833 U.S. participants, 49% were women as compared to 40% of the 90,914 non-U.S. participants. Similar levels of participation were seen after the exclusion of sex-specific drug indications, and by therapeutic area for U.S. and non-U.S. sites.
Conclusions
Clinical trials are becoming increasingly multi-national, and the increasing representation of women across countries is promising. FDA approval processes ensure that global data used in the drug approval process meets regulatory standards and that data can be generalized to the U.S. population.

Greater political commitment needed to eliminate malaria

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 4 May 2019]

 

Commentary
|   28 April 2019
Greater political commitment needed to eliminate malaria
Authors: Minghui Ren
Abstract
Malaria-related mortality has a very high association with poverty rates, and the disease is most prevalent in low- and middle-income countries. To achieve the malaria-specific targets of the Sustainable Development Goals, malaria-endemic countries and development partners need to take concerted action to reduce malaria cases and deaths. Reaching all affected communities with malaria interventions requires strong political commitment and a significant expansion of international and domestic financial resources. World Malaria Day 2019 is an opportunity to review progress and challenges in this field.

Carriage of penicillin-non-susceptible pneumococci among children in northern Tanzania in the 13-valent pneumococcal vaccine era

International Journal of Infectious Diseases
April 2019 Volume 81, p1-254
https://www.ijidonline.com/issue/S1201-9712(19)X0004-1

 

Original Reports
Carriage of penicillin-non-susceptible pneumococci among children in northern Tanzania in the 13-valent pneumococcal vaccine era
Matilda Emgård, Sia E. Msuya, Balthazar M. Nyombi, Dominic Mosha, Lucia Gonzales-Siles, Rickard Nordén, Shadi Geravandi, Victor Mosha, Josefine Blomqvist, Sofie Franzén, Fredrika Sahlgren, Rune Andersson, Susann Skovbjerg
p156–166
Published online: January 24, 2019

Varicella Vaccination Among US Adolescents: Coverage and Missed Opportunities, 2007-2014

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 4 May 2019]

 

Journal of Public Health Management & Practice
May/June 2019 – Volume 25 – Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx
Research Full Report
Varicella Vaccination Among US Adolescents: Coverage and Missed Opportunities, 2007-2014
Leung, Jessica; Reagan-Steiner, Sarah; Lopez, Adriana; More
Journal of Public Health Management and Practice. 25(3):E19-E26, May/June 2019.

Venezuela’s migration crisis: a growing health threat to the region requiring immediate attention

Journal of Travel Medicine
Volume 26, Issue 2, 2019
https://academic.oup.com/jtm/issue/26/2

 

Editorial
Venezuela’s migration crisis: a growing health threat to the region requiring immediate attention
Jaime R Torres; Julio S Castro
Journal of Travel Medicine, Volume 26, Issue 2, 2019, tay141, https://doi.org/10.1093/jtm/tay141
As Venezuela’s humanitarian crisis worsens, Venezuelans are fleeing massively. South American countries unprepared to receiving such large migration flows, are struggling to respond to the needs of this population. Risk of spillover of various infectious diseases from Venezuela to other countries is a real health threat that requires immediate attention…

 

Definitions matter: migrants, immigrants, asylum seekers and refugees

Journal of Travel Medicine
Volume 26, Issue 2, 2019
https://academic.oup.com/jtm/issue/26/2

 

Definitions matter: migrants, immigrants, asylum seekers and refugees
P Douglas; M Cetron; P Spiegel
Journal of Travel Medicine, Volume 26, Issue 2, 2019, taz005, https://doi.org/10.1093/jtm/taz005
“Migrants can be defined in legal, administrative, research and statistical perspectives. While the term refugee is clear, migrants are a heterogeneous group with a lack of consensus in the definition. This means that the public perception of states being flooded with “migrants” in a world where national borders are disappearing, leads to the humanitarian aspects to migration being diluted. As health professionals clarity around the different migrant groups assists in the manner we undertake work and our advocacy role.”.

 

Embracing the challenges of migration medicine

Journal of Travel Medicine
Volume 26, Issue 2, 2019
https://academic.oup.com/jtm/issue/26/2

 

 

Embracing the challenges of migration medicine
Christina Greenaway, MD, MSc; Francesco Castelli, MD, FRCP (Lond), FFTM RCPS (Glasg), FESCMID
Journal of Travel Medicine, Volume 26, Issue 2, 2019, taz009, https://doi.org/10.1093/jtm/taz009
International migration is a global phenomenon that is growing in scope, complexity and impact. Migrants have several health disparities and promoting migrant health is increasingly recognized as a global public health priority. At this critical point in history we have the responsibility and opportunity to promote the health of the migrant population and to present a positive migrant narrative. This process has started and we need to continue the momentum.

Enhancing the health and safety of migrant workers

Journal of Travel Medicine
Volume 26, Issue 2, 2019
https://academic.oup.com/jtm/issue/26/2

 

Perspective
Enhancing the health and safety of migrant workers
Yuka Ujita, MD, PhD; Paul J Douglas, MBBS, FRACMA; Masatoki Adachi, MD, MSc
Journal of Travel Medicine, Volume 26, Issue 2, 2019, tay161, https://doi.org/10.1093/jtm/tay161
Migrant workers typically commence the migration process as healthy individuals. However, diverse circumstances throughout migration cycle may render them highly vulnerable to poor physical and mental health outcome. This Perspective explores current data, global health policies regarding health of migrant workers, and roles travel health providers can play.

Local trends in immunisation coverage across Africa

The Lancet
May 04, 2019 Volume 393Number 10183p1773-1910
https://www.thelancet.com/journals/lancet/issue/current

 

Comment
Local trends in immunisation coverage across Africa
Alexandre de Figueiredo, Fredrick Were
… In The Lancet, Jonathan Mosser and colleagues7 report estimates of diphtheria-pertussis-tetanus (DPT) vaccine coverage across the African continent at highly localised scales. With use of large-scale public health data from 49 African countries between 2000 and 2016, the authors identified local heterogeneities in DPT coverage and dropout between the first (DPT1) and third (DPT3) doses of the programme. The authors highlighted regions with persistently low coverage and high vaccine dropout rates and assessed coverage with a focus on the 80% coverage target for administrative-level units set by the Global Vaccine Action Plan (GVAP). Although geospatial models have been used previously for subnational coverage estimation in Africa,8 this analysis represents a major leap in both the breadth (a continental analysis) and the volume of data used.
Mosser and colleagues used almost 1 million immunisation records from 49 African countries by use of 183 household surveys hosted at the Global Health Data Exchange. Local coverage estimates were obtained with a Bayesian geostatistical model allowing coverage to be inferred at spatiotemporal points across Africa. Through this inference of yearly, spatially resolved estimates, Mosser and colleagues revealed novel insights in the geographical distribution of DPT coverage across Africa…

Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000–2016: a spatial and temporal modelling study

The Lancet
May 04, 2019 Volume 393Number 10183p1773-1910
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000–2016: a spatial and temporal modelling study
Jonathan F Mosser, William Gagne-Maynard, Puja C Rao, Aaron Osgood-Zimmerman, Nancy Fullman, Nicholas Graetz, Roy Burstein, Rachel L Updike, Patrick Y Liu, Sarah E Ray, Lucas Earl,
Aniruddha Deshpande, Daniel C Casey, Laura Dwyer-Lindgren, Elizabeth A Cromwell, David M Pigott, Freya M Shearer, Heidi Jane Larson, Daniel J Weiss, Samir Bhatt, Peter W Gething, Christopher J L Murray, Stephen S Lim, Robert C Reiner Jr, Simon I Hay
Open Access

The legal determinants of health: harnessing the power of law for global health and sustainable development

The Lancet
May 04, 2019 Volume 393Number 10183p1773-1910
https://www.thelancet.com/journals/lancet/issue/current

 

The Lancet Commissions
The legal determinants of health: harnessing the power of law for global health and sustainable development
Lawrence O Gostin, John T Monahan, Jenny Kaldor, Mary DeBartolo, Eric A Friedman, Katie Gottschalk, Susan C Kim, Ala Alwan, Agnes Binagwaho, Gian Luca Burci, Luisa Cabal, Katherine DeLand, Timothy Grant Evans, Eric Goosby, Sara Hossain, Howard Koh, Gorik Ooms, Mirta Roses Periago, Rodrigo Uprimny, Alicia Ely Yamin
Key messages
1 Law affects global health in multiple ways, by structuring, perpetuating, and mediating the social determinants of health.
2 Although law has been central to major public health achievements in the past, its capacity to advance global health with justice remains substantially underutilised, particularly among professionals in the fields of health and science.
3 The right to health, a legally binding norm, provides a foundation for advancing global health with justice and should underpin health-related legal reforms.
4 Every human being has a right to affordable, high quality health services. By embedding equity and accountability in all health systems, the law and the rule of law can achieve health coverage that is truly universal—delivering the Sustainable Development Goals’ promise to leave no one behind.
5 Although the ability to enforce compliance with international legal obligations is generally limited, and largely dependent on power dynamics and political will, creative mechanisms can foster compliance and help establish impetus for action.
6 Law can address the pressing health concerns of the 21st century, across diverse areas. From tobacco control, non-communicable diseases, and road safety, to health emergencies, law can implement fair, evidence-based interventions to save lives. The global health community should champion evidence-based legal interventions and build the research case for legal action.
7 Laws that stigmatise or discriminate against marginalised populations are especially harmful and exacerbate health disparities. The global health community must oppose laws that undermine the right to health and to equity.
8 To realise the full potential of law to advance global health with justice, the global health community should build legal capacity and establish a sustained dialogue with legislators, regulators, judges, civil society, and researchers.

Vaccine hesitancy: a generation at risk

The Lancet Child & Adolescent Health
May 2019 Volume 3Number 5p281-364
https://www.thelancet.com/journals/lanchi/issue/current

 

Editorial
Vaccine hesitancy: a generation at risk
The Lancet Child & Adolescent Health
Vaccine hesitancy is threatening the historical achievements made in reducing the burden of infectious diseases, which have plagued humanity for centuries. Only a collaborative effort between paediatricians, family doctors, parents, public health officials, governments, the technology sector, and civil society will allow myths and misinformation around vaccination to be dispelled. If we fail, the future health of unvaccinated children and their communities will suffer greatly.

Build a sustainable Belt and Road

Nature
Volume 569 Issue 7754, 2 May 2019
http://www.nature.com/nature/current_issue.html

 

Editorial | 01 May 2019
Build a sustainable Belt and Road
China’s vast Belt and Road Initiative [BRI] is on course to reshape research in the global south. Science leaders everywhere must work to make it transparent, green and free of conflicts of interest…. The BRI is the single largest project to build infrastructure worldwide since the Marshall Plan to rebuild Europe after the Second World War. Even conservative estimates suggest that the total cost will run to around US$1 trillion…

Advancing cancer genomics

Nature Genetics
Volume 51 Issue 5, May 2019
https://www.nature.com/ng/volumes/51/issues/5

 

Editorial | 01 May 2019
Advancing cancer genomics
The field of cancer genomics is currently in an exciting and fast-paced era. With advances in sequencing technologies, computational approaches and tumor models, understanding of cancer processes is at an all-time high, and the application of new methods to studying cancer holds great promise for developing important breakthroughs in cancer treatment and prevention.

Postvaccination Febrile Seizure Severity and Outcome

Pediatrics
May 2019, VOLUME 143 / ISSUE 5
https://pediatrics.aappublications.org/content/143/4?current-issue=y

 

Articles
Postvaccination Febrile Seizure Severity and Outcome
Lucy Deng, Heather Gidding, Kristine Macartney, Nigel Crawford, Jim Buttery, Michael Gold, Peter Richmond, Nicholas Wood
Pediatrics May 2019, 143 (5) e20182120; DOI: 10.1542/peds.2018-2120
This prospective cohort study is used to examine FSs in children aged ≤6 years in Australia, comparing severity and outcomes of VP-FSs to NVP-FSs.

 

 

Missed Opportunities for Rotavirus Vaccination

Pediatrics
May 2019, VOLUME 143 / ISSUE 5
https://pediatrics.aappublications.org/content/143/4?current-issue=y

 

Missed Opportunities for Rotavirus Vaccination
Bethany K. Sederdahl, Walter A. Orenstein, Jumi Yi, Evan J. Anderson, Robert A. Bednarczyk
Pediatrics May 2019, 143 (5) e20182498; DOI: 10.1542/peds.2018-2498
Using the 2014 NIS, we describe risk factors for being unvaccinated for rotavirus as well as missed opportunities for rotavirus vaccination.

Evaluation of a social protection policy on tuberculosis treatment outcomes: A prospective cohort study

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 4 May 2019)

 

Research Article
Evaluation of a social protection policy on tuberculosis treatment outcomes: A prospective cohort study
Tuberculosis (TB) still represents a major public health problem in Latin America, with low success and high default rates. Poor adherence represents a major threat for TB control and promotes emergence of drug-resistant TB. Expanding social protection programs could have a substantial effect on the global burden of TB; however, there is little evidence to evaluate the outcomes of socioeconomic support interventions. This study evaluated the effect of a conditional cash transfer (CCT) policy on treatment success and default rates in a prospective cohort of socioeconomically disadvantaged patients.
Karen Klein, Maria Paula Bernachea, Sarah Irribarren, Luz Gibbons, Cristina Chirico, Fernando Rubinstein
| published 30 Apr 2019 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002788

The Cost-Effectiveness and Value of Information of Three Influenza Vaccination Dosing Strategies for Individuals with Human Immunodeficiency Virus

PLoS One
http://www.plosone.org/
[Accessed 4 May 2019]

 

Research Article
The Cost-Effectiveness and Value of Information of Three Influenza Vaccination Dosing Strategies for Individuals with Human Immunodeficiency Virus
Bohdan Nosyk, Behnam Sharif, Huiying Sun, Curtis Cooper, Aslam H. Anis, on behalf of the CIHR Canadian HIV Trials Network Influenza Vaccine Research Group
Research Article | published 06 Dec 2011 PLOS ONE
https://doi.org/10.1371/journal.pone.0027059

 

Seasonal influenza: Knowledge, attitude and vaccine uptake among adults with chronic conditions in Italy

PLoS One
http://www.plosone.org/
[Accessed 4 May 2019]

 

Seasonal influenza: Knowledge, attitude and vaccine uptake among adults with chronic conditions in Italy
Gaia Bertoldo, Annalisa Pesce, Angela Pepe, Concetta Paola Pelullo, Gabriella Di Giuseppe, The Collaborative Working Group
Research Article | published 01 May 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0215978

Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US

PLoS One
http://www.plosone.org/
[Accessed 4 May 2019]

 

Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US
Samuel K. Peasah, Martin I. Meltzer, Michelle Vu, Danielle L. Moulia, Carolyn B. Bridges
Research Article | published 29 Apr 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0213499

Ebola vaccination in the Democratic Republic of the Congo

PNAS – Proceedings of the National Academy of Sciences of the United States of America
http://www.pnas.org/content/early/
[Accessed 4 May 2019]

Ebola vaccination in the Democratic Republic of the Congo
Chad R. Wells, Abhishek Pandey, Alyssa S. Parpia, Meagan C. Fitzpatrick, Lauren A. Meyers, Burton H. Singer, and Alison P. Galvani
PNAS first published April 29, 2019. https://doi.org/10.1073/pnas.1817329116
Significance
Using a spatial model that incorporates human mobility, poverty, and population density, we assessed the effectiveness of the vaccination program that was implemented during the 2018 Ebola outbreak in the Democratic Republic of the Congo. Our results demonstrate that even modest delays in initiating vaccination would have markedly eroded the impact of the program. The methodology we present has applicability for identifying areas at risk during outbreaks of other emerging and reemerging diseases, which is imperative for swift control.
Abstract
Following the April 2018 reemergence of Ebola in a rural region of the Democratic Republic of the Congo (DRC), the virus spread to an urban center by early May. Within 2 wk of the first case confirmation, a vaccination campaign was initiated in which 3,017 doses were administered to contacts of cases and frontline healthcare workers. To evaluate the spatial dynamics of Ebola transmission and quantify the impact of vaccination, we developed a geographically explicit model that incorporates high-resolution data on poverty and population density. We found that while Ebola risk was concentrated around sites initially reporting infections, longer-range dissemination also posed a risk to areas with high population density and poverty. We estimate that the vaccination program contracted the geographical area at risk for Ebola by up to 70.4% and reduced the level of risk within that region by up to 70.1%. The early implementation of vaccination was critical. A delay of even 1 wk would have reduced these effects to 33.3 and 44.8%, respectively. These results underscore the importance of the rapid deployment of Ebola vaccines during emerging outbreaks to containing transmission and preventing global spread. The spatiotemporal framework developed here provides a tool for identifying high-risk regions, in which surveillance can be intensified and preemptive control can be implemented during future outbreaks.

The Challenges of the Health Care Providers in Refugee Settings: A Systematic Review

Prehospital & Disaster Medicine
Volume 34 – Issue 2 – April 2019
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue

 

Comprehensive Review
The Challenges of the Health Care Providers in Refugee Settings: A Systematic Review
Nurtaç Kavukcu, Kerim Hakan Altıntaş
https://doi.org/10.1017/S1049023X19000190
Published online: 10 April 2019, pp. 188-196
All over the world, migration is affecting millions of people who either choose or are forced to leave their countries of origin. Health is considered to be one of the important aspects of migration that is highly influenced by the circumstances created by mobility within or across countries. In the context of forced migration, it is well-established that refugees are susceptible to various diseases and other health conditions which might occur or deteriorate based on the health systems and health care provision in receiving countries. There is a considerable amount of research on the challenges encountered by refugees in receiving countries, in terms of health care systems and services. However, there seems to be little focus on the health care providers’ perspectives of the challenges in health care provision in refugee settings. This review aims to explore some of the articles discussing the challenging issues surrounding refugee health from a provider’s perspective.

Expert Views on Their Role as Policy Advisor: Pilot Study for the Cases of Electromagnetic Fields, Particulate Matter, and Antimicrobial Resistance

Risk Analysis
Volume 39, Issue 5 Pages: 957-1191 May 2019
https://onlinelibrary.wiley.com/toc/15396924/current

 

Perspectives
Expert Views on Their Role as Policy Advisor: Pilot Study for the Cases of Electromagnetic Fields, Particulate Matter, and Antimicrobial Resistance
Pita Spruijt, Anne B. Knol, Arthur C. Petersen, Erik Lebret
Pages: 968-974
First Published: 31 October 2018

Evidence for causal links between education and maternal and child health: systematic review

Tropical Medicine & International Health
Volume 24, Issue 5 Pages: i-iv, 503-656 May 2019
https://onlinelibrary.wiley.com/toc/13653156/current

 

Reviews
Open Access
Evidence for causal links between education and maternal and child health: systematic review
Barbara S. Mensch, Erica K. Chuang, Andrea J. Melnikas, Stephanie R. Psaki
Pages: 504-522
First Published: 15 February 2019

Maternal interventions vigilance harmonization in low- and middle-income countries: Stakeholder meeting report; Amsterdam, May 1–2, 2018

Vaccine
Volume 37, Issue 20 Pages 2643-2764 (6 May 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/20

 

Conference info Abstract only
Maternal interventions vigilance harmonization in low- and middle-income countries: Stakeholder meeting report; Amsterdam, May 1–2, 2018
Ajoke Sobanjo-ter Meulen, Flor M. Munoz, David C. Kaslow, Keith P. Klugman, … Andy Stergachis
Pages 2643-2650

Trends and spatial distribution of MMR vaccine coverage in Brazil during 2007–2017

Vaccine
Volume 37, Issue 20 Pages 2643-2764 (6 May 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/20

 

Short communication Abstract only
Trends and spatial distribution of MMR vaccine coverage in Brazil during 2007–2017
Flávia C. Pacheco, Giovanny V.A. França, Guilherme A. Elidio, Carla Magda Allan S. Domingues, … Dirce B. Guilhem
Pages 2651-2655

Vaccine-preventable diseases and immunisation coverage among migrants and non-migrants worldwide: A scoping review of published literature, 2006 to 2016

Vaccine
Volume 37, Issue 20 Pages 2643-2764 (6 May 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/20

 

Research article Abstract only
Vaccine-preventable diseases and immunisation coverage among migrants and non-migrants worldwide: A scoping review of published literature, 2006 to 2016
Nadia A. Charania, Nina Gaze, Janice Y. Kung, Stephanie Brooks
Pages 2661-2669

Determinants of satisfaction with information and additional information-seeking behaviour for the pertussis vaccination given during pregnancy

Vaccine
Volume 37, Issue 20 Pages 2643-2764 (6 May 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/20

 

Research article Abstract only
Determinants of satisfaction with information and additional information-seeking behaviour for the pertussis vaccination given during pregnancy
Richard M. Clarke, Pauline Paterson, Miroslav Sirota
Pages 2712-2720

A complementary approach to the vaccination promotion continuum: An immunization-specific motivational-interview training for nurses

Vaccine
Volume 37, Issue 20 Pages 2643-2764 (6 May 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/20

 

Research article Abstract only
A complementary approach to the vaccination promotion continuum: An immunization-specific motivational-interview training for nurses
Arnaud Gagneur, Julie Bergeron, Virginie Gosselin, Anne Farrands, Geneviève Baron
Pages 2748-2756

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

PloS one
[25 Apr 2019, 14(4):e0215251]
Influenza vaccination of pregnant women in Paris, France: Knowledge, attitudes and practices among midwives.
P Loubet, C Nguyen, E Burnet, O Launay –
Abstract
INTRODUCTION: In France, midwives have been authorized to prescribe vaccines since 2016. Yet vaccination coverage among pregnant women remains low. Understanding the knowledge, attitudes and practices of midwives regarding influenza vaccination could help improve coverage.
METHODS: A cross-sectional survey was conducted in 2017 among midwives practicing in the public and private sectors in Paris using an online questionnaire. Multivariate logistic regression analysis of the data was conducted.
RESULTS: The response rate was 31% (n = 208/669). Overall, knowledge of influenza vaccine recommendations and of vaccine safety and effectiveness was high except regarding new-born immunity and influenza vaccine characteristics. Only 10% of midwives systematically prescribed the vaccine. Reported influenza vaccine uptake among midwives was 39%.
CONCLUSION: Efforts to improve the knowledge of midwives regarding the safety and effectiveness of vaccinating pregnant women in order to prevent influenza infection in newborns are necessary. Increasing vaccine uptake in both midwives and pregnant women will require adjusting education strategies.

 

International Journal of Community Medicine and Public Health (IJCMPH)
Vol 6, No 5 (2019)
Original Research Articles
A retrospective study on timeliness of vaccination among children aged 0 to 23 months in a rural area of Pondicherry
P Subbiah, A Rajagopal, VK Chavada, KP Vasudevan
Abstract
Background: Immunization is the cost-effective public health intervention that prevents and protects against vaccine preventable diseases. The objective was to estimate the timeliness in receiving age appropriate vaccines and to study selected factors influencing the timeliness of age appropriate vaccines as per national immunization schedule among children aged 0 to 23 months in a rural area of Pondicherry.
Methods: A retrospective study was done at a Community Health Centre, Karikalampakkam, Pondicherry using data from immunization registers of children aged 0 to 23 months, who were born between July 01, 2013 to July 31, 2015. If the child was vaccinated within 7 days of the scheduled time, it was considered as timely vaccination.
Results: Out of 679 children, 52% were males and 48% were females. The median days of delay in vaccination were ranged from 1-171 days. The proportion and the median days of delay were increased progressively as the age of the child increased. The place of delivery was significantly associated with birth doses of OPV, Hepatitis B and BCG vaccination. There was a significant difference in timeliness of vaccination across the birth order of the children for the first, second and third doses of OPV and Pentavalent vaccines (p=0.02). Birth weight of the children was not statistically associated with vaccination delay.
Conclusions: Delay in vaccination in varying frequency was observed for the vaccines administered under the national immunisation schedule. Hence, the age-appropriate vaccinations should be given up-to-date as well as on time.

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 4 May 2019
Education
What It’s Like to Be Quarantined on a College Campus
Alia Wong May 2, 2019
A UCLA student talks about measles exposure at his school, his time in isolation from other students, and making a TikTok video to pass the time.

 

BBC
http://www.bbc.co.uk/
Accessed 4 May 2019
Health
Minister considers ‘all options’ to boost vaccine uptake
4 May 2019
Health secretary Matt Hancock has said he is willing to look at “all options” to boost England’s vaccination levels, including compulsory immunisation.

 

The Economist
http://www.economist.com/
Accessed 4 May 2019
[No new, unique, relevant content]

 

Financial Times
http://www.ft.com/home/uk
Accessed 4 May 2019
[No new, unique, relevant content]

 

Forbes
http://www.forbes.com/
Accessed 4 May 2019
May 3, 2019
Scientology Cruise Ship With Measles Case Returns To Sea — But Where Will It Be Able To Dock?
The ship seems headed to Curacao, but it’s unclear how the Dutch nation will respond.
ByvRachel SandlervvForbes Staff

 

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 4 May 2019
[No new, unique, relevant content]

Foreign Policy
http://foreignpolicy.com/
Accessed 4 May 2019
[No new, unique, relevant content]

 

The Guardian
http://www.guardiannews.com/
Accessed 4 May 2019
[No new, unique, relevant content]

 

New Yorker
http://www.newyorker.com/
Accessed 4 May 2019
[No new, unique, relevant content]

 

New York Times
http://www.nytimes.com/
Accessed 4 May 2019
Africa
May 4
Ebola Deaths Top 1,000 in Congo Amid Clinic Attacks
Hostility toward health workers continued to hamper efforts to contain the second-deadliest outbreak of the virus.

World
Scientology Cruise Ship Faces Renewed Quarantine at Home Port in Curacao
May 2
A Church of Scientology cruise ship quarantined by the Caribbean nation of St. Lucia for measles is due to arrive on Saturday back at its home port on the island of Curacao, where it will face similar restrictions, a top health official there said.

U.S.
As Measles Returns, U.S. States Look to Cut Vaccine Exemptions
May 2
Maine could soon prohibit parents from citing religious or personal beliefs to avoid vaccinating their children, making the U.S. state one of a half dozen cracking down during the nation’s largest measles outbreak in 25 years.

Europe
Merck Steps Up U.S. Measles Vaccine Production With Increased Demand
Merck & Co said on Wednesday it has increased production of the measles vaccine to meet an uptick in demand in the United States in the midst of the country’s biggest outbreak in 25 years.

U.S.
NY Officials Issue Fines, Close Schools in Measles Fight
Officials in New York closed more schools, issued more fines and lobbied the Legislature to eliminate religious exemptions for required vaccinations as part of efforts to contain a measles outbreak.

U.S.
Trump Tells Americans: Go Get Your Measles Vaccination
U.S. President Donald Trump on Friday urged Americans to protect themselves with the measles vaccination as the number of cases of the once-eradicated disease in the United States hit the highest levels since 2000.

Asia Pacific
Pakistan’s War on Polio Falters Amid Attacks on Health Workers and Mistrust
Pakistani officials had hoped that 2019 would be the year they declared victory against the disease. But attacks and mistrust of vaccinations make that goal unlikely.

 

Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 4 May 2019
Commentary
The Complicated Truth About Vaccines
By Michael Segal
May 1, 2019 6:38 pm ET
They can appear to be the proximate cause of a condition when they have nothing to do with the ultimate cause.

 

Washington Post
http://www.washingtonpost.com/
Accessed 4 May 2019
[No new, unique, relevant content]

Think Tanks et al

Think Tanks et al

Brookings
http://www.brookings.edu/
Accessed 4 May 2019
[No new relevant content]

 

Center for Global Development
http://www.cgdev.org/page/press-center
[No new relevant content]

 

CSIS
https://www.csis.org/
Accessed 4 May 2019
Podcast Episode
The New Era of Global Immunization
April 30, 2019 | By Nellie Bristol

 

Council on Foreign Relations
http://www.cfr.org/
May 3, 2019
Democratic Republic of Congo
Distrust at Core of Ebola Crisis in Eastern Congo
The Ebola vaccine is proving highly effective in Eastern Conog, but distrust of health workers, skepticism of the disease’s existence, and attacks on medical facilities are stymying progress.
Blog Post by John Campbell Africa in Transition

 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 4 May 2019
[No new relevant content]

Vaccines and Global Health: The Week in Review :: 27 April 2019

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_27 Apr 2019

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

WHO: Vaccines and the power to protect

Milestones :: Perspectives :: Research

WHO: Vaccines and the power to protect
25 April 2019
This week is World Immunization Week, which runs from April 24th to 30th. The campaign, celebrated worldwide, aims to champion the power of vaccines to protect our health, and prevent outbreaks.
This year’s #VaccinesWork campaign comes at a critical time and will involve all of us to ensure every person is vaccinated at the right time, and that we remain protected together.
:: Read the spotilight on vaccines
:: More on the World Immunization Week campaign
:: Watch the Facebook chat with Dr O’Brien on why immunization matters

Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization

Milestones :: Perspectives :: Research

SAGE – April 2019

Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
2-4 April 2019
(Full report will be published in the Weekly Epidemiological Record on 31 May 2019)
Report from Director, IVB and Regional Updates
:: The Director of the WHO Department of Immunization, Vaccines and Biologicals provided a preview of what the vision for the next decade of work in the vaccine and immunization field will entail and stressed four key aspects: (1) over the last many decades, the world has been on a trajectory of great advances in the development and health of communities; (2) however, the world in 2019 is increasingly uncertain and volatile with the risk of backsliding; (3) the vaccine and immunization agenda is being re-shaped with a central view toward equity, security and prosperity for all; and (4) vaccines and immunization are central to achieving the Sustainable Development Goals (SDGs), with at least 14 of 17 linked to achieving vaccine goals.
:: The next decade is an opportunity for the global community to address key issues and harness new solutions in vaccines and immunization while at the same time contributing to the broader global health agendas including not only the SDGs but also WHO’s “triple billion” goal as part of its 13th Programme of Work, Primary Health Care, and Universal Health Coverage.
:: Regional Offices highlighted major achievements and challenges. Of concern are the multiple outbreaks of measles and other vaccine-preventable diseases as these reflect weakened immunization systems. Fragile and conflict-ridden countries face challenges in sustaining immunization, as do many lower-middle-income countries in relation to financing. Several regions reported on efforts to increase life-course vaccination and on strengthening country decision making.

Report from Gavi, the Vaccine Alliance
:: Approvals of new and expanded vaccine programmes at the December 2018 Gavi Board reflect a shift from infant vaccination to a life-course approach, which aligns with the priorities of the 13th WHO Programme of Work.
:: The Gavi Board retreat on the Gavi 5.0 strategy focused on ways that the Alliance contributes to the SDG vision of leaving no one behind. Four key areas were highlighted including: vaccine introductions; reaching the under-immunized; financial and programmatic sustainability; and healthy markets and innovation.
:: In 2019-2020, Gavi will update its core policies on country eligibility and transition, co-financing, health system investment framework and gender. In addition, the policies will focus on a more differentiated approach to accelerate equitable vaccination coverage and use an evolving support model to further unlock domestic resources.

Data use and quality
:: Discussed were major findings and knowledge gaps around data quality and use, and possible interventions to strengthen governance, tools, assessment and improvement planning in order to use data for continuous quality improvement (CQI) for immunization program decision-making.
:: Considerable amounts of immunization and vaccine-preventable disease surveillance-related data are routinely collected and available nationally, regionally, and globally, though quality and access often remain challenging and more needs to be done to create a “culture of data use”.
:: The use of data was emphasized as one of the major drivers of ongoing improvement in data quality. Any information and communication technology solutions require adequate infrastructure, sustainable financing, political will and a skilled and motivated workforce.
:: SAGE will further discuss this extensive review of data use and data quality in order to make decisions on recommendations at a future SAGE meeting.

Update on the development of a post 2020 Global Immunization Strategy
(i) Interim review and lessons learnt report
:: SAGE welcomed the interim review and lessons learnt report on the Global Vaccine Action Plan (GVAP). The final report will be presented to SAGE in October 2019. This interim report aims to provide a differentiated view on the achievements and shortcomings of GVAP and inform the development of the post 2020 strategy.
:: Interim findings highlighted achievements such as the alignment of all global actors, a strong monitoring and evaluation framework, emphasis on data quality and the increased numbers of national immunization technical advisory groups (NITAGs).
:: Reported shortcomings included the perception of a top-down plan, little guidance to offer solutions to address challenges, and weaknesses in advocacy and communications.
:: Progress towards the GVAP goals occurred mainly in well-funded areas such as new vaccine
introduction.
(ii) Post 2020 strategy
:: SAGE welcomed the accelerated process to develop the post 2020 global immunization strategy. The strategy should provide a coherent framework allowing alignment with global health agendas and with partner strategies, but especially with regional and country plans.
:: The development of the new strategy was officially launched by WHO with the co-creation multicountry multi-stakeholder forum on 19-21 March 2019 which gathered 110 participants from 50 organisations and over 30 countries. At the forum, a three-level approach was adopted with:
o An overarching vision for the decade through 2030 which would be used by actors within and beyond the immunization community;
o A framework strategy for immunization stakeholders;
o A collection of global, regional and country goals, plans, partner strategies and disease
strategies.
:: The strategy will be developed over the next months and include a wide engagement process to assure that the new strategy is informed by country needs and focus. An advanced draft will be presented to SAGE in October 2019 before submission in 2020 to the WHO Executive Board and the World Health Assembly for endorsement.

RTS,S/AS01 Malaria Vaccine and the Malaria Vaccine Implementation Programme (MVIP)
:: The framework for policy decision on RTS,S/AS01 Malaria Vaccine was presented to SAGE for consideration and endorsement. This framework describes how the data from the pilot
implementation of the RTS,S/AS01 malaria vaccine in Ghana, Kenya and Malawi will be used to
inform future malaria vaccine recommendations.
:: SAGE endorsed the step-wise process laid out in the framework for review and use of data from the pilot studies:
o Step 1: Updated WHO recommendations on use of RTS,S/AS01 vaccine in Africa are possible if and when (a) safety signals observed in the Phase III trial are resolved, and (b) severe malaria or mortality data trends are assessed as consistent with a beneficial impact of the vaccine. This step could be as early as 24 months after vaccinations begin in the first pilot country of the MVIP.
o Step 2: Adjustments or refinements to WHO malaria vaccine recommendations may be
made based on the final MVIP data set which is expected to be available approximately 50 months after the start of vaccination in the last pilot country of the MVIP. The pilots are designed to establish the public health value of the fourth dose of the vaccine schedule.
:: The framework will be reviewed on 10 April 2019 by the Malaria Policy Advisory Committee with consideration for endorsement.
:: Regional- and country-level consultation will be important in the development of updated WHO recommendations on us of RTS,S/AS01 vaccine.

Polio
:: SAGE acknowledged progress towards poliovirus eradication albeit expressed concerns about areas consistently inaccessible for vaccination in parts of Afghanistan and Nigeria.
:: SAGE expressed concern about the large number of circulating vaccine-derived polioviruses, and the poor vaccination coverage with IPV in many countries.
:: SAGE noted that the IPV supply shortages are abating and will allow swift implementation of catchup campaigns.
:: In anticipation of the certification in 2019 of Wild Polio Virus Type 3 (WPV3) eradiation, SAGE discussed the potential switch from bOPV to mOPV1. While no decision was taken at this time, SAGE highlighted the very significant programmatic and regulatory challenges associated with such a switch.
:: SAGE endorsed guidelines for surveillance of poliovirus excretion among persons with primary immunodeficiencies.

Defeating meningitis by 2030: Global Roadmap
:: Meningitis remains a major public health challenge in regions and countries around the world. Cases and outbreaks continue to be highly feared. The magnitude of the problem varies dramatically between regions, but in all instances deaths and long-term sequelae due to meningitis leave a substantial mark.
:: SAGE was presented with the global strategy to ‘Defeat Meningitis by 2030’ which is being
developed by a WHO-led multi-organization initiative that includes partners addressing the specific organisms responsible for most causes of acute bacterial meningitis.
:: SAGE praised the development of a global roadmap for Defeating Meningitis by 2030 that will be shared for recommendation at the October SAGE meeting. The initiative was considered timely, as important advances are happening in the field of the bacterial meningitis pathogens.
:: SAGE assessed the proposed strategic structure and pillars as promising, albeit advised to review the wording of the visionary picture to ensure it is achievable.
:: SAGE acknowledged that there is not sufficient awareness about meningitis globally which results in public complacency, and that the constituency that has driven this global effort is the affected communities.

Ebola vaccines
:: WHO Health Emergencies Response provided an update on the epidemiology of the outbreak in the Democratic Republic of Congo (DRC) and on the status of the Ebola response in North Kivu and particularly noted the important contribution of vaccination in reducing transmission.
:: SAGE re-visited the possible vaccination strategies by reviewing epidemiological data and impact modelling. It concluded that ring vaccination currently remains the most effective strategy in this DRC Ebola outbreak. Geographic targeting should remain as a fall-back strategy. Mass vaccination and ring plus had less favourable overall impact for the doses used in the modelling.
:: SAGE reviewed epidemiological data from North Kivu for children below 1 year of age and for lactating women. Although clinical data on the safety and efficacy of the rVSV-ZEBOV-GP Ebola vaccine for these two specific groups are absent, SAGE considers that the high attack rates and high case fatality rates for these groups, together with the accumulating data on vaccine safety and efficacy for other groups, justify inclusion of children who are above the age of 6 months and of lactating women in the ongoing ring vaccination efforts in North Kivu.
:: SAGE strongly urged the implementation of studies to evaluate additional Ebola candidate vaccines, including where possible in pregnant and lactating women and in infants.

Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization

Milestones :: Perspectives :: Research
SAGE – April 2019

Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
2-4 April 2019
(Full report will be published in the Weekly Epidemiological Record on 31 May 2019)
Report from Director, IVB and Regional Updates
:: The Director of the WHO Department of Immunization, Vaccines and Biologicals provided a preview of what the vision for the next decade of work in the vaccine and immunization field will entail and stressed four key aspects: (1) over the last many decades, the world has been on a trajectory of great advances in the development and health of communities; (2) however, the world in 2019 is increasingly uncertain and volatile with the risk of backsliding; (3) the vaccine and immunization agenda is being re-shaped with a central view toward equity, security and prosperity for all; and (4) vaccines and immunization are central to achieving the Sustainable Development Goals (SDGs), with at least 14 of 17 linked to achieving vaccine goals.
:: The next decade is an opportunity for the global community to address key issues and harness new solutions in vaccines and immunization while at the same time contributing to the broader global health agendas including not only the SDGs but also WHO’s “triple billion” goal as part of its 13th Programme of Work, Primary Health Care, and Universal Health Coverage.
:: Regional Offices highlighted major achievements and challenges. Of concern are the multiple outbreaks of measles and other vaccine-preventable diseases as these reflect weakened immunization systems. Fragile and conflict-ridden countries face challenges in sustaining immunization, as do many lower-middle-income countries in relation to financing. Several regions reported on efforts to increase life-course vaccination and on strengthening country decision making.

Report from Gavi, the Vaccine Alliance
:: Approvals of new and expanded vaccine programmes at the December 2018 Gavi Board reflect a shift from infant vaccination to a life-course approach, which aligns with the priorities of the 13th WHO Programme of Work.
:: The Gavi Board retreat on the Gavi 5.0 strategy focused on ways that the Alliance contributes to the SDG vision of leaving no one behind. Four key areas were highlighted including: vaccine introductions; reaching the under-immunized; financial and programmatic sustainability; and healthy markets and innovation.
:: In 2019-2020, Gavi will update its core policies on country eligibility and transition, co-financing, health system investment framework and gender. In addition, the policies will focus on a more differentiated approach to accelerate equitable vaccination coverage and use an evolving support model to further unlock domestic resources.

Data use and quality
:: Discussed were major findings and knowledge gaps around data quality and use, and possible interventions to strengthen governance, tools, assessment and improvement planning in order to use data for continuous quality improvement (CQI) for immunization program decision-making.
:: Considerable amounts of immunization and vaccine-preventable disease surveillance-related data are routinely collected and available nationally, regionally, and globally, though quality and access often remain challenging and more needs to be done to create a “culture of data use”.
:: The use of data was emphasized as one of the major drivers of ongoing improvement in data quality. Any information and communication technology solutions require adequate infrastructure, sustainable financing, political will and a skilled and motivated workforce.
:: SAGE will further discuss this extensive review of data use and data quality in order to make decisions on recommendations at a future SAGE meeting.

Update on the development of a post 2020 Global Immunization Strategy
(i) Interim review and lessons learnt report
:: SAGE welcomed the interim review and lessons learnt report on the Global Vaccine Action Plan (GVAP). The final report will be presented to SAGE in October 2019. This interim report aims to provide a differentiated view on the achievements and shortcomings of GVAP and inform the development of the post 2020 strategy.
:: Interim findings highlighted achievements such as the alignment of all global actors, a strong monitoring and evaluation framework, emphasis on data quality and the increased numbers of national immunization technical advisory groups (NITAGs).
:: Reported shortcomings included the perception of a top-down plan, little guidance to offer solutions to address challenges, and weaknesses in advocacy and communications.
:: Progress towards the GVAP goals occurred mainly in well-funded areas such as new vaccine
introduction.
(ii) Post 2020 strategy
:: SAGE welcomed the accelerated process to develop the post 2020 global immunization strategy. The strategy should provide a coherent framework allowing alignment with global health agendas and with partner strategies, but especially with regional and country plans.
:: The development of the new strategy was officially launched by WHO with the co-creation multicountry multi-stakeholder forum on 19-21 March 2019 which gathered 110 participants from 50 organisations and over 30 countries. At the forum, a three-level approach was adopted with:
o An overarching vision for the decade through 2030 which would be used by actors within and beyond the immunization community;
o A framework strategy for immunization stakeholders;
o A collection of global, regional and country goals, plans, partner strategies and disease
strategies.
:: The strategy will be developed over the next months and include a wide engagement process to assure that the new strategy is informed by country needs and focus. An advanced draft will be presented to SAGE in October 2019 before submission in 2020 to the WHO Executive Board and the World Health Assembly for endorsement.

RTS,S/AS01 Malaria Vaccine and the Malaria Vaccine Implementation Programme (MVIP)
:: The framework for policy decision on RTS,S/AS01 Malaria Vaccine was presented to SAGE for consideration and endorsement. This framework describes how the data from the pilot
implementation of the RTS,S/AS01 malaria vaccine in Ghana, Kenya and Malawi will be used to
inform future malaria vaccine recommendations.
:: SAGE endorsed the step-wise process laid out in the framework for review and use of data from the pilot studies:
o Step 1: Updated WHO recommendations on use of RTS,S/AS01 vaccine in Africa are possible if and when (a) safety signals observed in the Phase III trial are resolved, and (b) severe malaria or mortality data trends are assessed as consistent with a beneficial impact of the vaccine. This step could be as early as 24 months after vaccinations begin in the first pilot country of the MVIP.
o Step 2: Adjustments or refinements to WHO malaria vaccine recommendations may be
made based on the final MVIP data set which is expected to be available approximately 50 months after the start of vaccination in the last pilot country of the MVIP. The pilots are designed to establish the public health value of the fourth dose of the vaccine schedule.
:: The framework will be reviewed on 10 April 2019 by the Malaria Policy Advisory Committee with consideration for endorsement.
:: Regional- and country-level consultation will be important in the development of updated WHO recommendations on us of RTS,S/AS01 vaccine.

Polio
:: SAGE acknowledged progress towards poliovirus eradication albeit expressed concerns about areas consistently inaccessible for vaccination in parts of Afghanistan and Nigeria.
:: SAGE expressed concern about the large number of circulating vaccine-derived polioviruses, and the poor vaccination coverage with IPV in many countries.
:: SAGE noted that the IPV supply shortages are abating and will allow swift implementation of catchup campaigns.
:: In anticipation of the certification in 2019 of Wild Polio Virus Type 3 (WPV3) eradiation, SAGE discussed the potential switch from bOPV to mOPV1. While no decision was taken at this time, SAGE highlighted the very significant programmatic and regulatory challenges associated with such a switch.
:: SAGE endorsed guidelines for surveillance of poliovirus excretion among persons with primary immunodeficiencies.

Defeating meningitis by 2030: Global Roadmap
:: Meningitis remains a major public health challenge in regions and countries around the world. Cases and outbreaks continue to be highly feared. The magnitude of the problem varies dramatically between regions, but in all instances deaths and long-term sequelae due to meningitis leave a substantial mark.
:: SAGE was presented with the global strategy to ‘Defeat Meningitis by 2030’ which is being
developed by a WHO-led multi-organization initiative that includes partners addressing the specific organisms responsible for most causes of acute bacterial meningitis.
:: SAGE praised the development of a global roadmap for Defeating Meningitis by 2030 that will be shared for recommendation at the October SAGE meeting. The initiative was considered timely, as important advances are happening in the field of the bacterial meningitis pathogens.
:: SAGE assessed the proposed strategic structure and pillars as promising, albeit advised to review the wording of the visionary picture to ensure it is achievable.
:: SAGE acknowledged that there is not sufficient awareness about meningitis globally which results in public complacency, and that the constituency that has driven this global effort is the affected communities.

Ebola vaccines
:: WHO Health Emergencies Response provided an update on the epidemiology of the outbreak in the Democratic Republic of Congo (DRC) and on the status of the Ebola response in North Kivu and particularly noted the important contribution of vaccination in reducing transmission.
:: SAGE re-visited the possible vaccination strategies by reviewing epidemiological data and impact modelling. It concluded that ring vaccination currently remains the most effective strategy in this DRC Ebola outbreak. Geographic targeting should remain as a fall-back strategy. Mass vaccination and ring plus had less favourable overall impact for the doses used in the modelling.
:: SAGE reviewed epidemiological data from North Kivu for children below 1 year of age and for lactating women. Although clinical data on the safety and efficacy of the rVSV-ZEBOV-GP Ebola vaccine for these two specific groups are absent, SAGE considers that the high attack rates and high case fatality rates for these groups, together with the accumulating data on vaccine safety and efficacy for other groups, justify inclusion of children who are above the age of 6 months and of lactating women in the ongoing ring vaccination efforts in North Kivu.
:: SAGE strongly urged the implementation of studies to evaluate additional Ebola candidate vaccines, including where possible in pregnant and lactating women and in infants.

 

Malaria vaccine pilot launched in Malawi :: Partnership welcomes launch of first malaria vaccine pilot

Milestones :: Perspectives :: Research
Malaria

Malaria vaccine pilot launched in Malawi
23 April 2019 News release
WHO welcomes the Government of Malawi’s launch of the world’s first malaria vaccine today in a landmark pilot programme. The country is the first of three in Africa in which the vaccine, known as RTS,S, will be made available to children up to 2 years of age; Ghana and Kenya will introduce the vaccine in the coming weeks.

Malaria remains one of the world’s leading killers, claiming the life of one child every two minutes. Most of these deaths are in Africa, where more than 250 000 children die from the disease every year. Children under 5 are at greatest risk of its life-threatening complications. Worldwide, malaria kills 435 000 people a year, most of them children.

“We have seen tremendous gains from bed nets and other measures to control malaria in the last 15 years, but progress has stalled and even reversed in some areas. We need new solutions to get the malaria response back on track, and this vaccine gives us a promising tool to get there,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “The malaria vaccine has the potential to save tens of thousands of children’s lives.”…

::::::

Partnership welcomes launch of first malaria vaccine pilot
Funding agencies hail important step for the world’s first malaria vaccine
Geneva, 23 April 2019 – Malaria vaccine pilots will be a crucial test for a potentially valuable new tool in the fight against the disease, the three agencies funding the vaccine pilots said following the launch of the first one in Malawi.

The pilots, which will also launch soon in Kenya and Ghana, will aim to vaccinate around 360,000 children per year in the three countries to evaluate the feasibility of delivering the required four doses of RTS,S in real-life settings, the vaccine’s potential role in reducing childhood deaths and its safety in the context of routine use.

Gavi, the Vaccine Alliance, the Global Fund to Fight AIDS, Tuberculosis and Malaria and Unitaid are together providing just under US$ 50 million to fund the first phase of the pilots. Ministries of Health in Ghana, Kenya and Malawi will implement the pilots, in coordination with WHO.

“Malaria is still one of the biggest killers of children worldwide, taking the lives of over 200,000 children every year,” said Dr Seth Berkley, CEO of Gavi. “These pilots will be crucial to determine the part this vaccine could play in reducing the burden this disease continues to place on the world’s poorest countries.”

“To step up the fight against malaria, we need every available tool,” said Peter Sands, Executive Director of the Global Fund. “If this pilot shows that RTS,S is a cost-effective tool against malaria, it will help us save more children’s lives.”

“The malaria vaccine is an exciting innovation that complements the global health community’s efforts to end the malaria  epidemic,” said Lelio Marmora, Executive Director of Unitaid. “It is also a shining example of the kind of inter-agency coordination that we need. We look forward to learning how the vaccine can be integrated for greatest impact into our work.”

In clinical trials the vaccine was found to prevent approximately 4 in 10 malaria cases, as well as 3 in 10 cases of life-threatening severe malaria. It also reduced severe malaria anaemia, the most common reason children die from the disease, by 60%.

A 4-dose schedule is required, with the first dose given as soon as possible after five months of age, doses two and three given at monthly intervals after that, and the fourth dose given 15–18 months after the third dose. The vaccine will not be available in all regions of the countries, nor will it be given to adults or children outside the target age group.

In the Phase 3 trial the vaccine was generally well tolerated, with adverse reactions comparable to those of other childhood vaccines. The European Medicines Agency (EMA) carried out a scientific assessment of RTS,S and concluded that the vaccine has an acceptable safety profile in a scientific opinion issued in July 2015.

The vaccine is being considered as a complementary malaria control tool to be added to the core package of WHO-recommended measures for malaria prevention. This includes the routine use of insecticide-treated bednets, indoor spraying with insecticides and the timely use of malaria testing and treatment.

 

Over 20 million children worldwide missed out on measles vaccine annually in past 8 years, creating a pathway to current global outbreaks – UNICEF

Milestones :: Perspectives :: Research

Measles

Over 20 million children worldwide missed out on measles vaccine annually in past 8 years, creating a pathway to current global outbreaks – UNICEF
NEW YORK, 25 April 2019 – An estimated 169 million children missed out on the first dose of the measles vaccine between 2010 and 2017, or 21.1 million children a year on average, UNICEF said today.

Widening pockets of unvaccinated children have created a pathway to the measles outbreaks hitting several countries around the world today.

“The ground for the global measles outbreaks we are witnessing today was laid years ago,” said Henrietta Fore, UNICEF Executive Director. “The measles virus will always find unvaccinated children. If we are serious about averting the spread of this dangerous but preventable disease, we need to vaccinate every child, in rich and poor countries alike.”

In the first three months of 2019, more than 110,000 measles cases were reported worldwide – up nearly 300 per cent from the same period last year. An estimated 110,000 people, most of them children, died from measles in 2017, a 22 per cent increase from the year before.

Two doses of the measles vaccine are essential to protect children from the disease. However, due to lack of access, poor health systems, complacency, and in some cases fear or skepticism about vaccines, the global coverage of the first dose of the measles vaccine was reported at 85 per cent in 2017, a figure that has remained relatively constant over the last decade despite population growth. Global coverage for the second dose is much lower, at 67 per cent. The World Health Organization recommends a threshold of 95 per cent immunization coverage to achieve so-called ‘herd immunity’.

Top ten high-income countries where children not vaccinated with the first measles vaccine dose 2010 – 2017:
1. United States: 2,593,000
2. France: 608,000
3. United Kingdom: 527,000
4. Argentina: 438,000
5. Italy: 435,000
6. Japan: 374,000
7. Canada: 287,000
8. Germany: 168,000
9. Australia: 138,000
10. Chile: 136,000

In high income countries, while coverage with the first dose is 94 per cent, coverage for the second dose drops to 91 per cent, according to the latest data.

The United States tops the list of high-income countries with the most children not receiving the first dose of the vaccine between 2010 and 2017, at more than 2.5 million. It is followed by France and the United Kingdom, with over 600,000 and 500,000 unvaccinated infants, respectively, during the same period.

In low- and middle-income countries, the situation is critical. In 2017, for example, Nigeria had the highest number of children under one year of age who missed out on the first dose, at nearly 4 million. It was followed by India (2.9 million), Pakistan and Indonesia (1.2 million each), and Ethiopia (1.1 million).

Worldwide coverage levels of the second dose of the measles vaccines are even more alarming. Of the top 20 countries with the largest number of unvaccinated children in 2017, 9 have not introduced the second dose. Twenty-countries in sub-Saharan Africa have not introduced the necessary second dose in the national vaccination schedule, putting over 17 million infants a year at higher risk of measles during their childhood.

UNICEF, with partners such as the Measles and Rubella Initiative and Gavi, the Vaccine Alliance, is helping address this measles crisis by:
:: Negotiating vaccine prices: the cost of the measles vaccine is now at an all-time low;
:: Helping countries identify underserved areas and unreached children;
:: Procuring vaccines and other immunization supplies;
:: Supporting supplementary vaccination campaigns to address gaps in routine immunization coverage;
:: Working with relevant countries to introduce the second dose of the measles vaccine in the national immunization schedule. Cameroon, Liberia and Nigeria are on track to do so in 2019.
:: Introducing innovations like the use of solar power and mobile technologies to maintain vaccines at the right temperature.

“Measles is far too contagious,” said Fore. “It is critical not only to increase coverage but also to sustain vaccination rates at the right doses to create an umbrella of immunity for everyone.”

::::::

Statement from Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research, on FDA’s continued confidence in the safety and effectiveness of the measles, mumps, and rubella (MMR) vaccine
April 22, 2019
The FDA is a public health agency that always strives to use the best available scientific evidence to promote and protect the well being of individuals. It deeply concerns us when we see preventable diseases such as measles or mumps reemerging in the United States and threatening our communities. The World Health Organization recently named vaccine hesitancy one of the top 10 threats to global health. In this time of multiple measles outbreaks, and as we approach National Infant Immunization Week, we want to underscore our continued confidence in the safety and effectiveness of the vaccines that are highly successful at preventing – in some cases, nearly eradicating – preventable diseases.

The MMR vaccine has been approved in the United States for nearly 50 years to prevent measles, mumps and rubella (also known as German Measles). As a result of its use, measles and rubella were completely eradicated in the United States, and mumps cases decreased by 99%. Large well-designed studies have confirmed the safety and effectiveness of the MMR vaccine and have demonstrated that administration of the vaccine is not associated with the development of autism. However we’re seeing an increasing number of outbreaks of measles in communities across the country, including those in New York, New Jersey, Washington, California, and Michigan.

Considered eradicated within the U.S. since 2000, measles has persisted in other areas of the world where the vaccine is not as readily available, including countries in Europe, Asia, the Pacific Islands, and Africa. Unvaccinated U.S. residents may be exposed to measles while they are abroad and bring the disease back into the U.S. and spread it to others. Worldwide, about 20 million people get measles each year. According to the Centers for Disease Control and Prevention (CDC), there have also been outbreaks of mumps reported. It’s an urgent public health priority to monitor these diseases and raise awareness of the importance of timely immunizations, especially as outbreaks are taking hold among unvaccinated populations in this country…

We cannot state strongly enough – the overwhelming scientific evidence shows that vaccines are among the most effective and safest interventions to both prevent individual illness and protect public health.

Vaccinating against measles, mumps and rubella not only protects us and our children, it protects people who can’t be vaccinated, including children with compromised immune systems due to illness and its treatment, such as cancer.

We do not take lightly our responsibility to ensure the safety and effectiveness of vaccines, and work diligently to assess safety and effectiveness of all licensed vaccines for their intended uses. The MMR vaccine is very effective at protecting people against measles, mumps, and rubella. It also prevents complications caused by these diseases. And we have nearly 50 years of experience and evidence supporting that fact. In fact, according to the CDC, two doses of the MMR vaccine beginning at 12 months of age (the recommended dosing schedule) are 97% effective against measles, 88% effective against mumps, and 97% effective for rubella.

Like many medical products, the MMR vaccine has known potential side effects that are generally mild and short-lived, such as rash and fever. If parents have concerns about these side effects, we recommend that they speak with their health care providers about the benefits and risks of vaccines, along with the potential consequences of not vaccinating against diseases.

The FDA will continue to closely monitor these outbreaks of vaccine-preventable diseases alongside our federal partners at CDC and the Department of Health and Human Services, and will provide any new information about vaccine safety or effectiveness to the public. But just to be clear, the FDA has determined that the MMR vaccine is both safe and effective in preventing these diseases. We join our colleagues at HHS, CDC, National Institutes of Health and state and local health departments across the country in the continued effort to encourage vaccinations against these preventable diseases…

::::::

Featured Journal Content

The Lancet
Apr 27, 2019 Volume 393Number 10182p1669-1772, e39
https://www.thelancet.com/journals/lancet/issue/current
Editorial
Measles eradication: a goal within reach, slipping away
The Lancet
Prior to the introduction of the measles, mumps and rubella vaccine (MMR) in 1963, an estimated 3 to 4 million people in the USA contracted measles annually. As of April 22, 626 children in the USA have become infected with the virus so far in 2019. This fact has led to urgent Congressional hearings, understandably alarmed national news coverage, and the introduction of legislation to address the outbreak. Measles was declared eliminated in the USA in 2000, but the resurgence of the disease and its continued prominence globally are causes for great concern.

In the past 5 years, 75% of measles cases in the USA have occurred within more closed, religious communities such as the Amish in the Midwest and Somali migrants in Minnesota. According to the US Centers for Disease Control and Prevention, 91% of US children between the ages of 19 and 35 months receive MMR vaccinations. But within New York’s ultra-Orthodox Jewish community, for example, the rate is as low as 60%. These communities tend to be extremely close knit, have large families and young populations, and are fairly isolated from their surrounding communities. 90% of unvaccinated people exposed to measles will become infected, and, in communities such as these, even a small rate of vaccination hesitancy could potentially pose an enormous risk for a larger epidemic.

The current measles outbreak has become a major political issue in America. In New York City, Mayor Bill de Blasio controversially ordered mandatory vaccinations for specific areas of Williamsburg, Brooklyn—areas with heavily Orthodox Jewish populations—with a threat of a US$1000 fine. So far, six states have introduced legislation that would limit or eliminate the ability to claim religious or personal exemptions from vaccination for children. In the USA, anti-vaccine views don’t align neatly with political poles. But the fact that views seem to be hardening is an ominous echo of the political divisions that have prevented the near-unanimous scientific consensus on global climate change from being more broadly accepted in the USA. The science on vaccines is just as reliable, and the prospect of vaccination becoming another front in a political cold war could presage incalculable harm.

Global measles deaths have declined by over 80% since 2000—from 550 100 deaths to 89 780 deaths in 2016. But, according to WHO, there have been over 112 000 confirmed measles cases globally to date in 2019—nearly half of these in Africa, an increase of 700% over the same period in 2018. Europe has also seen a 300% increase in measles infection, with the German state of Brandenburg ordering mandatory vaccination at kindergartens. In 2018, 85% of children had received one dose of the two-dose MMR vaccine, while only 67% had received both. WHO reports that vaccine-hesitant parents often find misinformation online, and engagement, listening, and information provided by medical professionals are often the best ways to address concerns. While conflict and infrastructure are also major drivers of the current outbreak in Venezuela, Madagascar, and other nations, WHO called vaccine hesitancy one of its top ten threats to global health in 2019.

Removing vaccine exemptions for non-medical reasons has proven effective in the past. In 2015, California outlawed non-medical vaccination exemptions for school admissions and the vaccination rate rose to greater than 95%. And while we must carefully balance the needs of public health with religious rights, vaccine hesitancy isn’t just a personal issue. With a condition as contagious as measles, the choice not to vaccinate leaves the immunocompromised and children too young to be vaccinated at risk of infection.

Measles continues to spread within the USA and internationally in isolated, under-resourced and conflict-riven areas. The USA spends around $2 billion on vaccination programmes annually, but further government investment and community engagement are required, in America and globally: from efforts to communicate the effectiveness of vaccination and the dangers of diseases parents may have no first-hand knowledge of, to making vaccination as easy as possible by providing the option of community and home vaccination for large families, families with limited means, or vulnerable populations. Fifty-six years ago, millions faced measles every year. Today, only a bare handful do, and that success should spur us to make the effort to engage, inform, and ensure that measles is controlled globally once and for all.

Health for all

Featured Journal Content

Science
26 April 2019 Vol 364, Issue 6438
http://www.sciencemag.org/current.dtl
Editorial
Health for all
By Seth Berkley, Henrietta Fore
Science26 Apr 2019 : 309
Summary
Imagine a world where affordable, quality health care is available to every person, and where infectious disease and infant and maternal mortality are as rare in the poorest parts as they are in wealthier countries. The world has already come a long way toward meeting this goal. But to finish the job, we need to change our thinking.

To be sure, the incidence of child mortality and cases of deadly infectious diseases have dropped dramatically around the world. For example, polio, which once paralyzed a thousand children every day, has been eliminated from all but three countries, with just 33 cases last year. Measles cases, despite a recent, alarming global surge, are now a fraction of what they were four decades ago. All this was made possible because global health organizations and the governments of lower-income countries have worked together to provide the most vulnerable communities access to essential health care interventions, such as clean water, sanitation, and vaccinations.

And yet, 1 in 10 children are still missing out. Most are the hardest to reach, whether they live in remote rural villages, conflict zones, among the swelling numbers of displaced people, or in rapidly growing urban slums where they might be undetected by formal health systems. Meeting their needs will require focusing more on health interventions that have both the greatest reach and are conduits to other health services for vulnerable communities. Childhood vaccination does precisely this. Vaccination reaches more children—more than 85%, who are inoculated against a range of infectious diseases—than any other health intervention globally.
When a child gets access to vaccines, it benefits that child’s community. With vaccines come supply chains, logistics, cold storage, trained health care staff, data monitoring, disease surveillance, and health care records. Parents and siblings often come along with the child who is being vaccinated, giving them potential access to a host of other health interventions—from neonatal and maternal health care to malaria prevention measures, and sexual and reproductive health and education.

Achieving health for all will also require a change in mindset. We must examine the barriers that deny health care to so many others. Such barriers can take different practical, cultural, or social forms, but identifying them can inform the development of new tailored solutions. If parents have too far to travel, for example, then build more health facilities closer to those who need them. Similarly, the lack of after-hours vaccination clinics or the use of male vaccinators in some settings can prevent or deter attendance. Also, traditional paper medical records may make it difficult for health care workers to know who is missing out because parents may rarely attend the same clinic twice.

This new mindset will require a shift in business models. Instead of seeking solutions that have the greatest utilitarian value, it could be better to look for innovative solutions that have an intended disproportionate impact, largely benefiting the few rather than the many. For example, in Tanzania, the Electronic Immunization Register, a tablet-based system, is giving vaccinators access to records across entire regions regardless of which clinic they are in. This is enabling them to proactively track which children are missing out.

As the 2030 deadline looms for the United Nations Sustainable Development Goals (SDGs), targets driving a broad range of development efforts today, providing health for all is likely to become increasingly more difficult. The good news is that nations have already taken the first major step with the SDG Global Action Plan, a commitment made last year by global health agencies to unite around efforts to accelerate progress. The hope is to start implementing a plan in September 2019. Health for all is achievable, but this vision requires new thinking by everyone.